Follow Novo Nordisk to never miss an important update.
Novo Nordisk is paying up to 2.6 billion dollars to license a weight-loss drug called HRS-1596 from Jiangsu Hengrui, the largest drugmaker in China. This deal gives Novo Nordisk the rights to develop and sell the treatment everywhere in the world.
While Novo Nordisk already leads the market with Wegovy, this move shows it is aggressively buying up new technology to stay ahead of rivals. Licensing a drug that is already in development helps the company fill its pipeline with more options as it looks for the next generation of treatments beyond its current hits.
Source: Reuters
Novo Nordisk's chief executive expects weight-loss pills to capture about 50 percent of the global obesity market by 2030. This marks a shift from today's market, which is dominated by weekly injections like Wegovy.
Moving toward pills is a logical step for the company to reach more patients and lower the burden of treatment. Novo is already testing several oral versions of its medicines, which could help it stay ahead of rivals as the market moves away from needles.
Source: Reuters
The chief executive told the Financial Times that the company is open to upgrading its listing in New York. While the stock already trades in the US, a more formal listing could help it reach a wider group of American investors. This is a move to match the company's massive presence in the US market, where most of its sales happen. It does not change the underlying business, but it shows management is focused on making the stock easier for global funds to own.
Source: Reuters
Novo Nordisk is paying up to 1.3 billion dollars to license technology from Nanexa. This technology is designed to make drugs last longer in the body, which could mean patients need fewer injections for treatments like Wegovy or Ozempic.
This is a smart move to stay ahead of rivals. Even though Novo Nordisk leads the market now, patients much prefer fewer needles. If the company can turn its weekly shots into monthly ones, it makes its products harder for competitors to replace and more convenient for millions of people to use.
Source: WSJ
Novo Nordisk reported that its newest experimental weight-loss drug helped patients lose an average of about 12 percent of their body weight. The results from this late-stage trial, which is the final phase of testing before a drug can be approved for the public, showed the treatment was more effective than a competing drug from Eli Lilly.
This is a major win because the obesity market is becoming a two-horse race between Novo and Lilly. Proving that its next generation of medicine can outperform the current competition helps Novo protect its lead as older drugs eventually lose their patent protection and face cheaper generic rivals.
Source: Reuters
Management has cleared its own profit targets for eight straight quarters, often by a wide margin, showing they have a firm grip on how quickly they can scale production.
| Expectation | |
|---|---|
| EPS | $0.76 |
| Revenue | $11.22B |
Follow Novo Nordisk to get the latest and most important updates.
Follow NVO